Literature DB >> 35618430

Type III-A CRISPR systems as a versatile gene knockdown technology.

Walter T Woodside1, Nikita Vantsev2,3, Ryan J Catchpole3, Sandra C Garrett4, Sara Olson4, Brenton R Graveley4, Michael P Terns1,2,3.   

Abstract

CRISPR-Cas systems are functionally diverse prokaryotic antiviral defense systems, which encompass six distinct types (I-VI) that each encode different effector Cas nucleases with distinct nucleic acid cleavage specificities. By harnessing the unique attributes of the various CRISPR-Cas systems, a range of innovative CRISPR-based DNA and RNA targeting tools and technologies have been developed. Here, we exploit the ability of type III-A CRISPR-Cas systems to carry out RNA-guided and sequence-specific target RNA cleavage for establishment of research tools for post-transcriptional control of gene expression. Type III-A systems from three bacterial species (L. lactis, S. epidermidis, and S. thermophilus) were each expressed on a single plasmid in E. coli, and the efficiency and specificity of gene knockdown was assessed by northern blot and transcriptomic analysis. We show that engineered type III-A modules can be programmed using tailored CRISPR RNAs to efficiently knock down gene expression of both coding and noncoding RNAs in vivo. Moreover, simultaneous degradation of multiple cellular mRNA transcripts can be directed by utilizing a CRISPR array expressing corresponding gene-targeting crRNAs. Our results demonstrate the utility of distinct type III-A modules to serve as specific and effective gene knockdown platforms in heterologous cells. This transcriptome engineering technology has the potential to be further refined and exploited for key applications including gene discovery and gene pathway analyses in additional prokaryotic and perhaps eukaryotic cells and organisms.
© 2022 Woodside et al.; Published by Cold Spring Harbor Laboratory Press for the RNA Society.

Entities:  

Keywords:  CRISPR; Cas; RNAi; gene knockdown; mRNA degradation; type III

Mesh:

Substances:

Year:  2022        PMID: 35618430      PMCID: PMC9297841          DOI: 10.1261/rna.079206.122

Source DB:  PubMed          Journal:  RNA        ISSN: 1355-8382            Impact factor:   5.636


  94 in total

Review 1.  RNAi mechanisms and applications.

Authors:  Daniel Kim; John Rossi
Journal:  Biotechniques       Date:  2008-04       Impact factor: 1.993

2.  SigmaE is an essential sigma factor in Escherichia coli.

Authors:  A De Las Peñas; L Connolly; C A Gross
Journal:  J Bacteriol       Date:  1997-11       Impact factor: 3.490

Review 3.  The next generation of CRISPR-Cas technologies and applications.

Authors:  Adrian Pickar-Oliver; Charles A Gersbach
Journal:  Nat Rev Mol Cell Biol       Date:  2019-08       Impact factor: 94.444

Review 4.  Conformational regulation of CRISPR-associated nucleases.

Authors:  Ryan N Jackson; Paul Bg van Erp; Samuel H Sternberg; Blake Wiedenheft
Journal:  Curr Opin Microbiol       Date:  2017-06-21       Impact factor: 7.934

5.  The ribonuclease activity of Csm6 is required for anti-plasmid immunity by Type III-A CRISPR-Cas systems.

Authors:  Kawanda Foster; Joshua Kalter; Walter Woodside; Rebecca M Terns; Michael P Terns
Journal:  RNA Biol       Date:  2018-08-01       Impact factor: 4.652

6.  Structure of the CRISPR interference complex CSM reveals key similarities with cascade.

Authors:  Christophe Rouillon; Min Zhou; Jing Zhang; Argyris Politis; Victoria Beilsten-Edmands; Giuseppe Cannone; Shirley Graham; Carol V Robinson; Laura Spagnolo; Malcolm F White
Journal:  Mol Cell       Date:  2013-10-10       Impact factor: 17.970

7.  Ribonuclease P processes polycistronic tRNA transcripts in Escherichia coli independent of ribonuclease E.

Authors:  Bijoy K Mohanty; Sidney R Kushner
Journal:  Nucleic Acids Res       Date:  2007-11-02       Impact factor: 16.971

8.  Conditional tolerance of temperate phages via transcription-dependent CRISPR-Cas targeting.

Authors:  Gregory W Goldberg; Wenyan Jiang; David Bikard; Luciano A Marraffini
Journal:  Nature       Date:  2014-08-31       Impact factor: 49.962

9.  Bipartite recognition of target RNAs activates DNA cleavage by the Type III-B CRISPR-Cas system.

Authors:  Joshua R Elmore; Nolan F Sheppard; Nancy Ramia; Trace Deighan; Hong Li; Rebecca M Terns; Michael P Terns
Journal:  Genes Dev       Date:  2016-02-04       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.